Hospital

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

A pharmacist-physician model significantly reduces wait times for atrial fibrillation care, enhancing patient access and treatment effectiveness in underserved areas.

Replacing animal products—particularly processed meats—with plant-based foods, including some processed options, can lower cardiometabolic risk and offer pharmacists practical counseling opportunities alongside medication therapy.

Explore all 16 agreements struck thus far between pharmaceutical companies and the White House to adhere to most favored nation pricing for drugs sold in the United States.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

The FDA cited human factors unrelated to the drug's efficacy as the reason for rejection.

Pharmacists are transforming patient care in 2026, enhancing clinical outcomes through innovative practices and expanded responsibilities in health systems.

Pharmacists should know about migraine treatments, such as lasmiditan, to effectively treat and educate patients with acute migraine.

RegeneCyte's HPC therapy shows promise in treating long COVID symptoms, with 85% of patients reporting fatigue relief.

The FDA approved the first dual-agent eye drops for presbyopia, offering a groundbreaking solution for age-related near vision loss.

Research data show that weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.

Shawn Riser Taylor, PharmD, CPP, CDCES, reflects on a research career shaped by a commitment to patient-driven inquiry and a passion for collaborative, learner-engaged projects.

CMS announces the selection of 15 high-cost drugs for Medicare price negotiations, aiming to reduce prescription costs for older adults and taxpayers.

Key updates include treatment thresholds, dietary recommendations, and management strategies.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

Updated guidelines on PA call for expanded screening, treatment, and monitoring, creating opportunities for pharmacists to screen all patients with hypertension.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.

Pharmacists secure patient safety by suggesting naloxone with opioid medications based on the MME thresholds, comedications, risk factors, and state regulations.

Explore how radio frequency identification (RFID) technology enhances medication safety, operational efficiency, and patient care in health care and pharmacy settings.

Reducing alcohol intake alongside GLP-1 therapy may significantly improve outcomes for patients with obesity or diabetes risk.

Interest in intravenous push administration of antibiotics is regaining popularity as fluid shortages arise.

Ben Long, MD, and Weston Blakeslee, PhD, discuss how pharmacists can integrate automated SMS tools to reduce readmissions while minimizing workflow burden.

Research reveals COVID-19's lasting effects on brain health, highlighting cognitive impairments in patients with long COVID even after recovery.

Recent research links depression to increased risk of Lewy body dementia and Parkinson disease, emphasizing the need for early detection and awareness.

Pharmacists are essential in guiding patients taking TNF inhibitors regarding supplement use, the risks of "immune boosters," and potential immunomodulatory therapy interactions.

Using wildcard hard-stop pharmacy preparation instructions in the electronic health record system significantly improved REMs documentation compliance at our institution.